Our Leadership

Our Leadership

Our focus is to achieve our mission and fulfill our vision.
That’s what drives us.

Our focus is to achieve our mission and fulfill our vision.
That’s what drives us.

Gerry Brunk, MBA
Chief Scientific Officer

José M. Lora, PhD

At enGene, Jose is part of the executive team and is responsible for scientific strategy and execution. Prior to joining enGene, Jose was Vice President, Research at Synlogic, a clinical-stage biopharmaceutical company in Cambridge, MA dedicated to the application of Synthetic Biology to the discovery and development of therapies for metabolic and immune-mediated diseases, and cancer. In this capacity, Jose built and led the Immunomodulation Group and was responsible for Synlogic’s first clinical program in immuno-oncology, SYNB1891, a strain of E. coli engineered to produce a STING agonist. Prior to joining Synlogic, Jose worked at Constellation Pharmaceuticals, a chromatin and epigeneticis-focused company in Cambridge, where he was responsible for Preclinical Sciences (Pharmacology, DMPK, Tox) and Immunology (inflammation and immuno-oncology), most recently serving as VP, Immunology/Immuno-Oncology. At Constellation he made critical contributions to both clinical programs (BET and EZH2) at all stages of development. His team was also responsible for the immuno-oncology pipeline at Constellation, as well as the immuno-oncology pipeline developed with Genentech during a strategic collaboration between both companies. Prior to Constellation, Jose served as Director and Head of Immuno-Epigenetics Biology at GlaxoSmithKline in the UK, and was a co-founder of EpiNova, a GSK entrepreneurial unit focused on the discovery and development of medicines targeting epigenetic factors that control the immune response. Prior to joining GSK, Jose served as Head of In Vivo Pharmacology in the Immunology, Autoimmunity and Transplantation Department at Roche in Palo Alto, CA, and as Senior Scientist in the Immuno-Inflammation Department at Millennium Pharmaceuticals in Cambridge, MA. Jose received his PhD from the University of Seville, in his native Spain, and did postdoctoral work at Brown University and the University of Utah. He is co-author of numerous publications, including papers in Nature, Nature Immunology, Journal of Experimental Medicine, and PNAS
Gerry Brunk, MBA
Chief Scientific Officer

José M. Lora, PhD


At enGene, Jose is part of the executive team and is responsible for scientific strategy and execution. Prior to joining enGene, Jose was Vice President, Research at Synlogic, a clinical-stage biopharmaceutical company in Cambridge, MA dedicated to the application of Synthetic Biology to the discovery and development of therapies for metabolic and immune-mediated diseases, and cancer. In this capacity, Jose built and led the Immunomodulation Group and was responsible for Synlogic’s first clinical program in immuno-oncology, SYNB1891, a strain of E. coli engineered to produce a STING agonist. Prior to joining Synlogic, Jose worked at Constellation Pharmaceuticals, a chromatin and epigeneticis-focused company in Cambridge, where he was responsible for Preclinical Sciences (Pharmacology, DMPK, Tox) and Immunology (inflammation and immuno-oncology), most recently serving as VP, Immunology/Immuno-Oncology. At Constellation he made critical contributions to both clinical programs (BET and EZH2) at all stages of development. His team was also responsible for the immuno-oncology pipeline at Constellation, as well as the immuno-oncology pipeline developed with Genentech during a strategic collaboration between both companies. Prior to Constellation, Jose served as Director and Head of Immuno-Epigenetics Biology at GlaxoSmithKline in the UK, and was a co-founder of EpiNova, a GSK entrepreneurial unit focused on the discovery and development of medicines targeting epigenetic factors that control the immune response. Prior to joining GSK, Jose served as Head of In Vivo Pharmacology in the Immunology, Autoimmunity and Transplantation Department at Roche in Palo Alto, CA, and as Senior Scientist in the Immuno-Inflammation Department at Millennium Pharmaceuticals in Cambridge, MA. Jose received his PhD from the University of Seville, in his native Spain, and did postdoctoral work at Brown University and the University of Utah. He is co-author of numerous publications, including papers in Nature, Nature Immunology, Journal of Experimental Medicine, and PNAS